AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22253270 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam (6 mg initial loading dose followed by 3 mg maintenance doses)
Number of subjects: 54
Study 22253270 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 54
Study 20375406 — intervention group
Group type: EXPERIMENTAL
Intervention: T12PR24 (telaprevir for 12 weeks + peginterferon alfa-2a and ribavirin for 24 weeks)
Number of subjects: 453
Study 20375406 — intervention group
Group type: EXPERIMENTAL
Intervention: T24PR48 (telaprevir for 24 weeks + peginterferon alfa-2a and ribavirin for 48 weeks)
Number of subjects: 453
Study 20375406 — intervention group
Group type: EXPERIMENTAL
Intervention: T24P24 (telaprevir and peginterferon alfa-2a for 24 weeks)
Number of subjects: 453
Study 20375406 — intervention group
Group type: COMPARATOR
Intervention: PR48 (control group, peginterferon alfa-2a and ribavirin for 48 weeks)
Number of subjects: 453
Study 17377863 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel + hemoclips (Group II)
Number of subjects: 200
Study 17377863 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery + hemoclips (Group I)
Number of subjects: 200
Study 15728298 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (3 x 100 mg/day)
Number of subjects: 42
Study 15728298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 11949645 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 40
Study 11949645 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 40
Study 9807845 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram/kg
Number of subjects: 120
Study 9807845 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol HCl 1.5 mg/kg
Number of subjects: 120
Study 9807845 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 0.3 mg/kg
Number of subjects: 120
Study 7665860 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (Cefotaxime + Metronidazole)
Number of subjects: 61
Study 7665860 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 61
Study 2526271 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (31/min)
Number of subjects: 14
Study 2526271 — intervention group
Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 14
Study 27008619 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterconditioning group
Number of subjects: 96
Study 27008619 — intervention group
Group type: COMPARATOR
Intervention: Extinction group
Number of subjects: 96
Study 27008619 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 28035736 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain rye porridges (40 g)
Number of subjects: 21
Study 28035736 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain rye porridges (55 g)
Number of subjects: 21
Study 28035736 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye porridge enriched with inulin: gluten proportions (9:3 g)
Number of subjects: 21
Study 28035736 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye porridge enriched with inulin: gluten proportions (6:6 g)
Number of subjects: 21
Study 28035736 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye porridge enriched with inulin: gluten proportions (3:9 g)
Number of subjects: 21
Study 28035736 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat bread (control, 55 g)
Number of subjects: 21
Study 25660206 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion to sleep deeper before a midday nap
Number of subjects: 0
Study 25660206 — intervention group
Group type: COMPARATOR
Intervention: Control tape before a midday nap
Number of subjects: 0
Study 25660206 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion
Number of subjects: 0
Study 23257734 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride citrate 20 mg
Number of subjects: 0
Study 23257734 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 0
Study 21091527 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-abrasive device (AM)
Number of subjects: 42
Study 21091527 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (LM)
Number of subjects: 42
Study 18805963 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant asparaginase preparation
Number of subjects: 32
Study 18805963 — intervention group
Group type: COMPARATOR
Intervention: Asparaginase medac
Number of subjects: 32
Study 16407508 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg per day (group 1)
Number of subjects: 422
Study 16407508 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg per day (group 2)
Number of subjects: 422
Study 16407508 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 422
Study 16407508 — intervention group
Group type: COMPARATOR
Intervention: Benazepril and Placebo (group 2)
Number of subjects: 422
Study 14585010 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous performance of pronouncing 'A' or 'B' and making a manual left or right response to arrows.
Number of subjects: 0
Study 14585010 — intervention group
Group type: COMPARATOR
Intervention: Alternative control procedure mixing manual and vocal tasks.
Number of subjects: 0
Study 11320566 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 74
Study 11320566 — intervention group
Group type: COMPARATOR
Intervention: Observation without treatment
Number of subjects: 74
Study 8795669 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 17
Study 8795669 — intervention group
Group type: COMPARATOR
Intervention: Control (UNDW)
Number of subjects: 17
Study 1505913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (13 to 15 mg/kg body wt/day)
Number of subjects: 14
Study 1505913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1505913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 14
Study 6440383 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy
Number of subjects: 44
Study 6440383 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 44
Study 30523504 — intervention group
Group type: EXPERIMENTAL
Intervention: UV skin damage visuals
Number of subjects: 2219
Study 30523504 — intervention group
Group type: COMPARATOR
Intervention: Mole removal visuals
Number of subjects: 2219
Study 30523504 — intervention group
Group type: COMPARATOR
Intervention: Other visual conditions
Number of subjects: 2219
Study 30523504 — intervention group
Group type: COMPARATOR
Intervention: Visual efficacy conditions
Number of subjects: 2219
Study 30223451 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based high-carbohydrate, low-fat (vegan) diet (n = 38)
Number of subjects: 75
Study 30223451 — intervention group
Group type: COMPARATOR
Intervention: Current diet (n = 37)
Number of subjects: 75
Study 27157029 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 28
Study 27157029 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 28
Study 27157029 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined participants (N = 26)
Number of subjects: 28
Study 27157029 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT
Number of subjects: 28
Study 24804364 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for patients only
Number of subjects: 823
Study 24804364 — intervention group
Group type: COMPARATOR
Intervention: No education
Number of subjects: 823
Study 22435936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 1173
Study 22435936 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment group
Number of subjects: 1173
Study 19307037 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific formula (DSF)
Number of subjects: 12
Study 19307037 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric standard fibre‐containing formula (SF)
Number of subjects: 12
Study 16306064 — intervention group
Group type: EXPERIMENTAL
Intervention: Certified facilities (intervention group)
Number of subjects: 170
Study 16306064 — intervention group
Group type: COMPARATOR
Intervention: Non-certified facilities (control group)
Number of subjects: 170
Study 14583133 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 3179
Study 10762503 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia with Lewy bodies (DLB)
Number of subjects: 155
Study 10762503 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular dementia (VaD)
Number of subjects: 155
Study 10762503 — intervention group
Group type: COMPARATOR
Intervention: Clinical scale assessment
Number of subjects: 155
Study 9041090 — intervention group
Group type: EXPERIMENTAL
Intervention: Amvisc
Number of subjects: 69
Study 9041090 — intervention group
Group type: EXPERIMENTAL
Intervention: Amvisc Plus
Number of subjects: 69
Study 9041090 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon
Number of subjects: 69
Study 9041090 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat
Number of subjects: 69
Study 1375684 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 48
Study 1375684 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 48
Study 1375684 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 48
Study 1375684 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 48
Study 1375684 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 48
Study 1375684 — intervention group
Group type: COMPARATOR
Intervention: Control (no inotropic therapy)
Number of subjects: 48
Study 3965373 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl acetate (RA) gel 3 mg
Number of subjects: 50
Study 3965373 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl acetate (RA) gel 6 mg
Number of subjects: 50
Study 3965373 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl acetate (RA) gel 9 mg
Number of subjects: 50
Study 3965373 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl acetate (RA) gel 18 mg
Number of subjects: 50
Study 3965373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30674038 — intervention group
Group type: EXPERIMENTAL
Intervention: BC 007 (ssDNA therapeutic)
Number of subjects: 0
Study 29575006 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat 50 mg
Number of subjects: 59
Study 29575006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 29575006 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat (doses of 12.5 mg and above)
Number of subjects: 59
Study 29575006 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of molidustat
Number of subjects: 59
Study 26442829 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC level(t) <4.0 ng/ml
Number of subjects: 528
Study 26442829 — intervention group
Group type: COMPARATOR
Intervention: TAC level(t) ≥4.0 ng/ml
Number of subjects: 528
Study 24580383 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural 0.75% levobupivacaine 12 ml with 1 ml (0.5 µg/kg) of dexmedetomidine
Number of subjects: 40
Study 24580383 — intervention group
Group type: COMPARATOR
Intervention: Epidural 0.75% levobupivacaine 12 ml with 1 ml of isotonic sodium chloride solution
Number of subjects: 40
Study 22114200 — intervention group
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale (BBS)
Number of subjects: 111
Study 22114200 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance‐Oriented Mobility Assessment total scale (POMA‐T)
Number of subjects: 111
Study 22114200 — intervention group
Group type: EXPERIMENTAL
Intervention: POMA balance subscale (POMA‐B)
Number of subjects: 111
Study 22114200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Gait Index (DGI)
Number of subjects: 111
Study 22114200 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline balance subgroup
Number of subjects: 111
Study 22114200 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sample
Number of subjects: 111
Study 20816902 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA.HIVA vaccination
Number of subjects: 0
Study 17701000 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial thinning
Number of subjects: 163
Study 17701000 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential thinning
Number of subjects: 163
Study 17701000 — intervention group
Group type: COMPARATOR
Intervention: Zona intact
Number of subjects: 163
Study 16697169 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipidic matricial form (M)
Number of subjects: 6
Study 16697169 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipidic physical blend formulation (PB)
Number of subjects: 6
Study 16697169 — intervention group
Group type: COMPARATOR
Intervention: Pulmicort Turbuhaler (control)
Number of subjects: 6
Study 12800415 — intervention group
Group type: EXPERIMENTAL
Intervention: Manshuailing Oral Liquid (MSL) 100 ml, 2 times a day for 4 months
Number of subjects: 90
Study 12800415 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with western drugs (cardiotonic, diuretic, coronary dilator, etc.)
Number of subjects: 90
Study 12800415 — intervention group
Group type: EXPERIMENTAL
Intervention: Manshuailing Oral Liquid (MSL) in patients with mixed heart failure (systolic and diastolic dysfunction)
Number of subjects: 90
Study 11193499 — intervention group
Group type: EXPERIMENTAL
Intervention: Intertrochanteric hip fracture treatment
Number of subjects: 60
Study 11193499 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 patients, mean age 62.4 years)
Number of subjects: 60
Study 9004441 — intervention group
Group type: COMPARATOR
Intervention: 0 mg GMDP
Number of subjects: 153
Study 9004441 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg GMDP
Number of subjects: 153
Study 9004441 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg GMDP
Number of subjects: 153
Study 9004441 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg GMDP
Number of subjects: 153
Study 1279948 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound scan
Number of subjects: 41
Study 1279948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical formula for estimating weight
Number of subjects: 41
Study 3976733 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher personality construct (abstract vs. concrete conceptual system)
Number of subjects: 454
Study 3976733 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupil variables (race, school behavior)
Number of subjects: 454
Study 29420997 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnosine 500 mg (2 capsules)
Number of subjects: 54
Study 29420997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 27959941 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medication
Number of subjects: 59
Study 27959941 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion
Number of subjects: 59
Study 25205644 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular procedure
Number of subjects: 0
Study 25205644 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 0
Study 23063851 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-Infant Transaction Program (n = 61)
Number of subjects: 118
Study 23063851 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 57)
Number of subjects: 118
Study 20660002 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine treatment
Number of subjects: 308
Study 20660002 — intervention group
Group type: COMPARATOR
Intervention: Antithyroid drugs (medical treatment)
Number of subjects: 308
Study 20660002 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TAO (regardless of treatment)
Number of subjects: 308
Study 20660002 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without TAO
Number of subjects: 308
Study 18822620 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg daily subcutaneously
Number of subjects: 82
Study 18822620 — intervention group
Group type: COMPARATOR
Intervention: Control group (no teriparatide)
Number of subjects: 82
Study 18822620 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 82
Study 16019582 — intervention group
Group type: EXPERIMENTAL
Intervention: Sahaja Yoga meditation (SYM)
Number of subjects: 50
Study 16019582 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 12200983 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (15 mg/kg/day) for 28 days
Number of subjects: 63
Study 12200983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 12200983 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 63
Study 10613070 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible time-counter during CPAP accommodation
Number of subjects: 20
Study 10613070 — intervention group
Group type: COMPARATOR
Intervention: No visible time-counter during CPAP accommodation
Number of subjects: 20
Study 10613070 — intervention group
Group type: COMPARATOR
Intervention: Subjective estimation of time with no visible counter
Number of subjects: 20
Study 7560219 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan applied after histamine reaction
Number of subjects: 9
Study 7560219 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan pre-treatment before histamine application
Number of subjects: 9
Study 7560219 — intervention group
Group type: EXPERIMENTAL
Intervention: Other phenols tested
Number of subjects: 9
Study 1951545 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (3 days intravenously and 4 days orally)
Number of subjects: 103
Study 1951545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 7012995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin (800 mg twice daily for 14 days)
Number of subjects: 16
Study 7012995 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (500 mg four times daily for 14 days)
Number of subjects: 16
Study 7012995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin
Number of subjects: 16
Study 7012995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin and Ampicillin
Number of subjects: 16
Study 31522159 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) at a dose of 70 mg once weekly for six months plus local debridement
Number of subjects: 45
Study 31522159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepidium sativum (LS; 1 gm tid for six weeks) plus local debridement
Number of subjects: 45
Study 31522159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of LS (1 gm tid for six weeks) and ALN (70 mg once weekly for six months) plus local debridement
Number of subjects: 45
Study 31522159 — intervention group
Group type: COMPARATOR
Intervention: Control group (local debridement only)
Number of subjects: 45
Study 28287324 — intervention group
Group type: EXPERIMENTAL
Intervention: Home delivery meal service providing energy‐dense, protein‐rich meals delivered 3 times per week
Number of subjects: 40
Study 28287324 — intervention group
Group type: COMPARATOR
Intervention: Control group continued their habitual diet
Number of subjects: 40
Study 25485857 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 0
Study 25485857 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet
Number of subjects: 0
Study 23673091 — intervention group
Group type: EXPERIMENTAL
Intervention: Low temperature (LT) group: 36.0 - 37.5°C
Number of subjects: 65
Study 23673091 — intervention group
Group type: COMPARATOR
Intervention: High temperature (HT) group: 37.5 - 38.3°C
Number of subjects: 65
Study 21239867 — intervention group
Group type: EXPERIMENTAL
Intervention: E170 insulin assay
Number of subjects: 77
Study 21239867 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of free insulin after PEG pre-treatment
Number of subjects: 77
Study 18434058 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5T magnetic field strength
Number of subjects: 16
Study 18434058 — intervention group
Group type: COMPARATOR
Intervention: 3T magnetic field strength
Number of subjects: 16
Study 18434058 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5T and 3T magnetic field strengths
Number of subjects: 16
Study 16401537 — intervention group
Group type: EXPERIMENTAL
Intervention: SaphLITE retractor system (group III)
Number of subjects: 110
Study 16401537 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bridge technique (group II)
Number of subjects: 110
Study 16401537 — intervention group
Group type: COMPARATOR
Intervention: Standard continuous skin incisions (group I)
Number of subjects: 110
Study 16401537 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 110
Study 12938815 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg per day
Number of subjects: 261
Study 12938815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 12938815 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 261
Study 10993031 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT alone (micronized E2 0.5 mg + micronized P4 100 mg)
Number of subjects: 57
Study 10993031 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT + T (micronized E2 0.5 mg + micronized P4 100 mcg + micronized T 1.25 mg)
Number of subjects: 57
Study 9441115 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT Accelerator
Number of subjects: 15
Study 9441115 — intervention group
Group type: COMPARATOR
Intervention: 3% saline alone
Number of subjects: 15
Study 1349485 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 53
Study 1349485 — intervention group
Group type: COMPARATOR
Intervention: 20 mg nitrendipine
Number of subjects: 53
Study 1349485 — intervention group
Group type: EXPERIMENTAL
Intervention: Casual blood pressure readings
Number of subjects: 53
Study 1349485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring
Number of subjects: 53
Study 1349485 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measured blood pressure
Number of subjects: 53
Study 1349485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure
Number of subjects: 53